Work

A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.tps3106

Authors: Naiyer A. Rizvi, Jeffrey R. Infante, Geoffrey Thomas Gibney, Erin Marie Bertino, Sarah A. Cooley, Kiki Lekatis, Jon M. Wigginton, Andres A. Gutierrez, Ashok Kumar Gupta, Su Young Kim, F. Stephen Hodi

Institutions: Memorial Sloan Kettering Cancer Center, Tennessee Oncology, Moffitt Cancer Center, The Ohio State University Wexner Medical Center, University of Minnesota, Bristol-Myers Squibb (United States), Dana-Farber Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2274852027

Cites:

Cited by: 7

Related to: 10